Patent Infringement lawsuit related to BRIDION: US Court rules in favor of Merck
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. District Court for the District of New Jersey ruled in favor of the company and found that Merck correctly calculated the Patent Term Extension period for the primary patent related to BRIDION (sugammadex). Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
The ruling from the U.S. District Court for the District of New Jersey affirms and validates Merck’s U.S. patent protection for BRIDION through at least January 2026.
“Merck’s science and technology was used to develop and launch BRIDION, and we’re pleased that the Court recognized the validity of our full patent extension period granted by the Patent Office,” said Jennifer Zachary, executive vice president and general counsel, Merck. “Innovations like these contribute to a broader ecosystem that allows us to continue investing in research and development to bring important new therapies and vaccines forward to the patients who need them.”
Read also: USFDA accepts application for Merck KEYTRUDA plus chemotherapy as treatment for Biliary Tract Cancer
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd